Bullfrog AI Holdings, Inc. - BFRG STOCK NEWS

BullFrog AI (NASDAQ: BFRG; BFRGW) announced that its VP of Artificial Intelligence, Dr. Enrique García-Rivera, will present at Google's inaugural Cancer AI Symposium on October 30, 2024, in Boston. The presentation will showcase BullFrog AI's use of AI in drug discovery and development, focusing on their proprietary bfLEAP™ platform. This platform integrates multimodal biological data to accelerate drug development, particularly in cancer research.

Dr. García-Rivera will highlight the company's collaboration with the Lieber Institute for Brain Development, demonstrating bfLEAP™'s versatility across various therapeutic areas. He will also introduce BullFrog AI's novel 'AlgoLLM' system for gene prioritization, which uses large language models to streamline the discovery of actionable insights in neuropsychiatric disorders and other diseases.

WallachBeth Capital announced the closing of BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) registered direct offering and concurrent private placement. The offering included:

• 1,565,000 shares of common stock (or equivalents)
• Common warrants to purchase up to 1,565,000 shares
• Combined purchase price of $2.00
• Gross proceeds of approximately $3.13 million

The warrants have an exercise price of $2.00 per share, are exercisable after six months, and expire five years from the initial exercise date. WallachBeth Capital, acted as sole placement agent for the offering.

BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) has closed a previously announced definitive agreement for a registered direct offering and concurrent private placement. The company sold an aggregate of 1,565,000 shares of common stock (or equivalents) and warrants to purchase up to 1,565,000 shares at a combined price of $2.00. The gross proceeds from the offering are expected to be approximately $3.13 million.

The warrants have an exercise price of $2.00 per share, are initially exercisable six months from issuance, and will expire five years from the initial exercise date. WallachBeth Capital, acted as the sole placement agent for the offering. The shares and pre-funded warrants were issued under an effective shelf registration statement, while the common warrants were offered through a private placement.

WallachBeth Capital announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has entered into a definitive agreement for a registered direct offering and concurrent private placement. The offering includes:

• 1,565,000 shares of common stock (or equivalents)
• Common warrants to purchase up to 1,565,000 shares
• Combined purchase price of $2.00
• Warrant exercise price of $2.00 per share

The gross proceeds are expected to be approximately $3.13 million. The closing is anticipated around October 21, 2024. WallachBeth Capital, is acting as the sole placement agent for this offering.

BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) has announced a registered direct offering and concurrent private placement for aggregate gross proceeds of $3.13 million. The offering includes:

- 1,565,000 shares of common stock (or equivalents)
- Common warrants to purchase up to 1,565,000 shares
- Combined purchase price of $2.00
- Warrant exercise price of $2.00 per share

The warrants will be initially exercisable six months from issuance and expire five years from the initial exercise date. The offering is expected to close around October 21, 2024. WallachBeth Capital, is acting as the sole placement agent for the offering.

BullFrog AI (NASDAQ: BFRG; BFRGW) has appointed Dr. John Baldoni to its Scientific Advisory Board. Dr. Baldoni brings over 40 years of pharmaceutical industry experience, including 29 years in R&D at GSK where he served as Senior Vice President of Platform and Technology Sciences. He is the co-founder of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium and former Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare.

Vin Singh, CEO of BullFrog AI, stated that Dr. Baldoni's experience in pharmaceutical R&D and leadership in technology-driven drug discovery will provide valuable insights for the commercialization of their bfLEAP™ platform. Dr. Baldoni expressed excitement about collaborating with BullFrog AI, recognizing the potential of the bfLEAP™ platform to transform complex biological data analysis in drug discovery and development.

BullFrog AI Holdings (NASDAQ: BFRG) announced new research supporting the potential of its drug candidate BF-114 in treating liver diseases. The study, published in Cell Reports and led by Dr. Lopa Mishra, provides evidence for the role of β2-spectrin in obesity, MASLD, MASH, and HCC. Key points:

• BF-114 targets β2-spectrin and may prevent liver disease progression
• Research strengthens the scientific foundation for BF-114
• BullFrog AI plans to use its AI platform to analyze single-cell data for further insights
• Dr. Mishra joins BullFrog AI's Scientific Advisory Board

The company aims to leverage these findings to advance BF-114's development and explore additional therapeutic applications.

BullFrog AI Holdings (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company's CEO, Vin Singh, will deliver a presentation that will be available on demand starting September 9, 2024, at 7:00am ET. Interested parties can access live and archived webcasts of the event through BullFrog AI's investor relations website at investors.bullfrogai.com. This participation provides an opportunity for the company to showcase its advancements in AI-driven drug discovery to a global investment audience.

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced significant progress in its collaboration with the Lieber Institute for Brain Development (LIBD) to uncover new insights into bipolar disorder (BD) pathways and potential drug targets. The research has identified specific molecular pathways associated with BD, enabling the discovery of new candidate drug targets.

Key findings include:

• Significant enrichment in 6 out of 68 clusters from the LIBD brain dataset
• Two substantially enriched clusters in the Dentate Gyrus
• One specific cluster associated with BD in the Dorsolateral Prefrontal Cortex
• Potential dysregulation of pro-inflammatory pathways
• Identification of novel pathways significant to BD pathophysiology

BullFrog AI is now focusing on validating these findings in wet lab settings and engaging with pharmaceutical partners to advance these discoveries.